Literature DB >> 18929125

Involvement of the Bcl2 gene family in the signaling and control of retinal ganglion cell death.

Robert W Nickells1, Sheila J Semaan, Cassandra L Schlamp.   

Abstract

Retinal ganglion cell death by apoptosis is a well-established outcome in the glaucomatous pathology of the retina. Extensive research into the molecular events underlying this process show us that members of the Bcl2 gene family play a critical role in the activation and control of ganglion cell death. Perhaps the most critical molecule at play is the pro-apoptotic protein BAX. Without BAX, ganglion cell somas appear to survive an optic nerve insult indefinitely. Once BAX is activated, however, the cell death program reaches an irreversible point, where the process cannot be blocked. Interacting with BAX are other members of this larger gene family, including the anti-apoptotic protein BCL-X, and several members of the BH3-only proteins that serve as sensors and activators of the cell death program. A hypothetical model of how all these molecules interact in glaucoma is presented.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18929125     DOI: 10.1016/S0079-6123(08)01129-1

Source DB:  PubMed          Journal:  Prog Brain Res        ISSN: 0079-6123            Impact factor:   2.453


  27 in total

1.  Variations in the rheostat model of apoptosis: what studies of retinal ganglion cell death tell us about the functions of the Bcl2 family proteins.

Authors:  Robert W Nickells
Journal:  Exp Eye Res       Date:  2010-03-15       Impact factor: 3.467

2.  Protective role of somatostatin receptor 2 against retinal degeneration in response to hypoxia.

Authors:  Massimo Dal Monte; Valentina Latina; Elena Cupisti; Paola Bagnoli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-07       Impact factor: 3.000

3.  The cell and molecular biology of glaucoma: mechanisms of retinal ganglion cell death.

Authors:  Robert W Nickells
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-05-04       Impact factor: 4.799

4.  Differentially expressed microRNAs in the aqueous humor of patients with exfoliation glaucoma or primary open-angle glaucoma.

Authors:  Michelle D Drewry; Pratap Challa; John G Kuchtey; Iris Navarro; Inas Helwa; Yanzhong Hu; Hongmei Mu; W Daniel Stamer; Rachel W Kuchtey; Yutao Liu
Journal:  Hum Mol Genet       Date:  2018-04-01       Impact factor: 6.150

5.  The role of Bcl-xL in mouse RPE cell survival.

Authors:  Sarah Medearis; Ian C Han; Jessica K Huang; Ping Yang; Glenn J Jaffe
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-08-17       Impact factor: 4.799

6.  [Complement activation after induction of ocular hypertension in an animal model].

Authors:  S Becker; S Reinehr; H Burkhard Dick; S C Joachim
Journal:  Ophthalmologe       Date:  2015-01       Impact factor: 1.059

7.  Early gene expression changes in the retinal ganglion cell layer of a rat glaucoma model.

Authors:  Ying Guo; Elaine C Johnson; William O Cepurna; Jennifer A Dyck; Tom Doser; John C Morrison
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-18       Impact factor: 4.799

8.  Primary cilia signaling mediates intraocular pressure sensation.

Authors:  Na Luo; Michael D Conwell; Xingjuan Chen; Christine Insinna Kettenhofen; Christopher J Westlake; Louis B Cantor; Clark D Wells; Robert N Weinreb; Timothy W Corson; Dan F Spandau; Karen M Joos; Carlo Iomini; Alexander G Obukhov; Yang Sun
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-20       Impact factor: 11.205

9.  Glaucoma-induced degeneration of retinal ganglion cells prevented by hypoxic preconditioning: a model of glaucoma tolerance.

Authors:  Yanli Zhu; Lihong Zhang; Jimena F Schmidt; Jeffrey M Gidday
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

10.  Protection of mouse retinal ganglion cell axons and soma from glaucomatous and ischemic injury by cytoplasmic overexpression of Nmnat1.

Authors:  Yanli Zhu; Lihong Zhang; Yo Sasaki; Jeffrey Milbrandt; Jeffrey M Gidday
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-02       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.